232 related articles for article (PubMed ID: 25916698)
21. B-cell lymphomas with concurrent MYC and BCL2 abnormalities other than translocations behave similarly to MYC/BCL2 double-hit lymphomas.
Li S; Seegmiller AC; Lin P; Wang XJ; Miranda RN; Bhagavathi S; Medeiros LJ
Mod Pathol; 2015 Feb; 28(2):208-17. PubMed ID: 25103070
[TBL] [Abstract][Full Text] [Related]
22. Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas.
Pillai RK; Sathanoori M; Van Oss SB; Swerdlow SH
Am J Surg Pathol; 2013 Mar; 37(3):323-32. PubMed ID: 23348205
[TBL] [Abstract][Full Text] [Related]
23. A clinician's guide to double hit lymphomas.
Cheah CY; Oki Y; Westin JR; Turturro F
Br J Haematol; 2015 Mar; 168(6):784-95. PubMed ID: 25529575
[TBL] [Abstract][Full Text] [Related]
24. Dual targeting of bromodomain-containing 4 by AZD5153 and BCL2 by AZD4320 against B-cell lymphomas concomitantly overexpressing c-MYC and BCL2.
Takimoto-Shimomura T; Tsukamoto T; Maegawa S; Fujibayashi Y; Matsumura-Kimoto Y; Mizuno Y; Chinen Y; Shimura Y; Mizutani S; Horiike S; Taniwaki M; Kobayashi T; Kuroda J
Invest New Drugs; 2019 Apr; 37(2):210-222. PubMed ID: 29931583
[TBL] [Abstract][Full Text] [Related]
25. Bright CD38 Expression by Flow Cytometric Analysis Is a Biomarker for Double/Triple Hit Lymphomas with a Moderate Sensitivity and High Specificity.
Alsuwaidan A; Pirruccello E; Jaso J; Koduru P; Garcia R; Krueger J; Doucet M; Chaudhry R; Fuda F; Chen W
Cytometry B Clin Cytom; 2019 Sep; 96(5):368-374. PubMed ID: 30734478
[TBL] [Abstract][Full Text] [Related]
26. [B-cell lymphomas with concurrent myc and bcl-2/IgH or bcl-6 translocations].
Luo DL; Liu YH; Zhang F; Xu FP; Yan LX; Chen J; Xu J; Luo XL; Zhuang HG
Zhonghua Bing Li Xue Za Zhi; 2013 Sep; 42(9):584-8. PubMed ID: 24314242
[TBL] [Abstract][Full Text] [Related]
27. Double-hit and double-expressor primary central nervous system lymphoma: Experience from North India of an infrequent but aggressive variant.
Parkhi M; Chatterjee D; Radotra BD; Bal A; Yadav BS; Tripathi M
Surg Neurol Int; 2023; 14():172. PubMed ID: 37292392
[TBL] [Abstract][Full Text] [Related]
28. "Triple hit" lymphomas: A retrospective cytology case series of an uncommon high grade B-cell malignancy with C-MYC, BCL-2 and BCL-6 rearrangements.
Eldessouki T; Hanley K; Hamadeh F; Oshilaja OO; Sturgis CD
Diagn Cytopathol; 2018 Sep; 46(9):807-811. PubMed ID: 30043475
[TBL] [Abstract][Full Text] [Related]
29. Impact of autograft-absolute lymphocyte count on survival in double/triple hit lymphomas post-autologous stem cell transplantation.
Porrata LF; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Villasboas JC; Paludo J; Markovic SN
Leuk Lymphoma; 2022 Oct; 63(10):2436-2443. PubMed ID: 35481444
[TBL] [Abstract][Full Text] [Related]
30. Advances in pathological understanding of high-grade B cell lymphomas.
Li S; Lin P; Medeiros LJ
Expert Rev Hematol; 2018 Aug; 11(8):637-648. PubMed ID: 29989509
[TBL] [Abstract][Full Text] [Related]
31. Do Double-Expressor High-Grade B-Cell Lymphomas Really Need Intensified Treatment? A Report from the Real-Life Series of High-Grade B-Cell Lymphomas Treated with Different Therapeutic Protocols at the Institute of Oncology Ljubljana.
Boltežar L; Rožman S; Gašljević G; Grčar Kuzmanov B; Jezeršek Novaković B
Biomedicines; 2024 Jan; 12(2):. PubMed ID: 38397877
[TBL] [Abstract][Full Text] [Related]
32. Targeting BCL2 with venetoclax is a promising therapeutic strategy for "double-proteinexpression" lymphoma with
Uchida A; Isobe Y; Asano J; Uemura Y; Hoshikawa M; Takagi M; Miura I
Haematologica; 2019 Jul; 104(7):1417-1421. PubMed ID: 30523053
[TBL] [Abstract][Full Text] [Related]
33. Double-hit and double-protein-expression lymphomas: aggressive and refractory lymphomas.
Sarkozy C; Traverse-Glehen A; Coiffier B
Lancet Oncol; 2015 Nov; 16(15):e555-e567. PubMed ID: 26545844
[TBL] [Abstract][Full Text] [Related]
34. Double- and triple-hit lymphomas can present with features suggestive of immaturity, including TdT expression, and create diagnostic challenges.
Moench L; Sachs Z; Aasen G; Dolan M; Dayton V; Courville EL
Leuk Lymphoma; 2016 Nov; 57(11):2626-35. PubMed ID: 26892631
[TBL] [Abstract][Full Text] [Related]
35. Targeting MYC and BCL2 by a natural compound for "double-hit" lymphoma.
Liu X; Xu S; Zhang J; Fan M; Xie J; Zhang B; Li H; Yu G; Liu Y; Zhang Y; Song J; Horne D; Chan WC; Chu X; Huang W
Hematol Oncol; 2022 Aug; 40(3):356-369. PubMed ID: 35482553
[TBL] [Abstract][Full Text] [Related]
36. Simultaneous targeting of XPO1 and BCL2 as an effective treatment strategy for double-hit lymphoma.
Liu Y; Azizian NG; Dou Y; Pham LV; Li Y
J Hematol Oncol; 2019 Nov; 12(1):119. PubMed ID: 31752970
[TBL] [Abstract][Full Text] [Related]
37. Double-hit lymphomas: current paradigms and novel treatment approaches.
Dunleavy K
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):107-12. PubMed ID: 25696842
[TBL] [Abstract][Full Text] [Related]
38. Generation and characteristics of a novel "double-hit" high grade B-cell lymphoma cell line DH-My6 with
Kikuchi H; Higuchi T; Hashida Y; Taniguchi A; Kamioka M; Taguchi T; Yokoyama A; Murakami I; Fujieda M; Daibata M
Oncotarget; 2018 Sep; 9(71):33482-33499. PubMed ID: 30323893
[TBL] [Abstract][Full Text] [Related]
39. Triple-hit B-cell Lymphoma With MYC, BCL2, and BCL6 Translocations/Rearrangements: Clinicopathologic Features of 11 Cases.
Wang W; Hu S; Lu X; Young KH; Medeiros LJ
Am J Surg Pathol; 2015 Aug; 39(8):1132-9. PubMed ID: 25828391
[TBL] [Abstract][Full Text] [Related]
40. ABT-199, a BH3 mimetic that specifically targets Bcl-2, enhances the antitumor activity of chemotherapy, bortezomib and JQ1 in "double hit" lymphoma cells.
Johnson-Farley N; Veliz J; Bhagavathi S; Bertino JR
Leuk Lymphoma; 2015 Jul; 56(7):2146-52. PubMed ID: 25373508
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]